Timothy F Cloughesy

Timothy F Cloughesy

UNVERIFIED PROFILE

Are you Timothy F Cloughesy?   Register this Author

Register author
Timothy F Cloughesy

Timothy F Cloughesy

Publications by authors named "Timothy F Cloughesy"

Are you Timothy F Cloughesy?   Register this Author

100Publications

3403Reads

17Profile Views

Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling.

Cell Metab 2019 Sep 11;30(3):525-538.e8. Epub 2019 Jul 11.

Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA; Department of Pathology, UCSD School of Medicine, La Jolla, CA 92093, USA; Moores Cancer Center, UCSD School of Medicine, La Jolla, CA 92093, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2019.06.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742496PMC
September 2019

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.

Clin Cancer Res 2019 Aug 7;25(16):4993-5001. Epub 2019 Jun 7.

Dana-Farber Program in Regulatory Science, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0820DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697596PMC
August 2019

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series.

CNS Oncol 2019 Jun 11;8(2):CNS35. Epub 2019 Jul 11.

Department of Neurology, University of California, Los Angeles, 710 Westwood Plaza RNRC #1-230, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns-2019-0007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713025PMC
June 2019

Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma.

J Neurooncol 2018 Sep 31;139(3):651-659. Epub 2018 May 31.

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2910-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126989PMC
September 2018

Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients.

Sci Rep 2018 09 26;8(1):14429. Epub 2018 Sep 26.

Department of Bioengineering, Henry Samueli School of Engineering, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-32397-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158293PMC
September 2018

Improving B Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation.

Tomography 2018 Sep;4(3):123-137

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18383/j.tom.2018.00017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173788PMC
September 2018

Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?

Neuro Oncol 2018 07;20(8):1144

Center for Neuro-Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280142PMC
July 2018

D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced Promoter Methylation.

Mol Cancer Res 2018 06 15;16(6):947-960. Epub 2018 Mar 15.

Neuro-Oncology Program, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-17-0367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984679PMC
June 2018

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

J Transl Med 2018 06 29;16(1):179. Epub 2018 Jun 29.

Northwest Biotherapeutics Inc., Bethesda, MD, USA.

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-018-1552-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026340PMC
June 2018

Platform trials arrive on time for glioblastoma.

Neuro Oncol 2018 05;20(6):723-725

UCLA Neuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961158PMC
May 2018

Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Neuro Oncol 2018 03;20(4):457-471

UCLA Neuro-Oncology Program, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article/20/4/457/448
Publisher Site
http://dx.doi.org/10.1093/neuonc/nox193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909663PMC
March 2018

A gene expression signature predicts recurrence-free survival in meningioma.

Oncotarget 2018 Mar 15;9(22):16087-16098. Epub 2018 Feb 15.

The University of Texas MD Anderson Cancer Center, Department of Translational Molecular Pathology, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.24498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882319PMC
March 2018

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Neuro Oncol 2018 01;20(2):249-258

Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W, J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California, San Francisco, Helen Diller Cancer Center Building, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.H., J.P., R.W.); The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777496PMC
January 2018

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Neuro Oncol 2018 01;20(2):259-267

The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts (P.Y.W., J.D.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.dG.); University of California San Francisco, San Francisco, California (M.D.P.); Duke University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, California (J.P., J.H., R.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777491PMC
January 2018

Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.

J Neurooncol 2017 Sep 1;134(2):357-362. Epub 2017 Jul 1.

Department of Neurology, Neuro-Oncology Program, University of California Los Angeles, Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2533-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135089PMC
September 2017

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

J Neurooncol 2017 Aug 25;134(1):177-188. Epub 2017 May 25.

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2506-9DOI Listing
August 2017

Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.

Exp Mol Pathol 2017 08 27;103(1):87-93. Epub 2017 Jun 27.

Divison of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, United States; Brain Research Institute, University of California-Los Angeles, Los Angeles, CA, United States; Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2017.06.006DOI Listing
August 2017

Adult Glioblastoma.

J Clin Oncol 2017 Jul 22;35(21):2402-2409. Epub 2017 Jun 22.

Brian M. Alexander, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; and Timothy F. Cloughesy, University of California Los Angeles, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.0119DOI Listing
July 2017

mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.

Mol Cell 2017 Jul 22;67(1):128-138.e7. Epub 2017 Jun 22.

Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093, USA; Department of Pathology, UCSD School of Medicine, La Jolla, CA 92093 USA; Moores Cancer Center, UCSD School of Medicine, La Jolla, CA 92093 USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2017.05.030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521991PMC
July 2017

Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine.

J Nucl Med 2017 May 6;58(5):689-696. Epub 2017 Apr 6.

Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.116.181693DOI Listing
May 2017

NovoTTF: where to go from here?

Neuro Oncol 2017 05;19(5):605-608

Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464445PMC
May 2017

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Neurotherapeutics 2017 04;14(2):307-320

UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-016-0507-6
Publisher Site
http://dx.doi.org/10.1007/s13311-016-0507-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398984PMC
April 2017

Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma.

J Neurooncol 2017 04 4;132(2):351-358. Epub 2017 Feb 4.

Divison of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, 10833 LeConte Avenue, CHS13-145B, 90095, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-017-2377-0
Publisher Site
http://dx.doi.org/10.1007/s11060-017-2377-0DOI Listing
April 2017

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.

Neuro Oncol 2017 01 31;19(1):89-98. Epub 2016 Aug 31.

UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z.); Dept. of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E., R.J.H., D.C.W., K.L., O.Z., W.B.P.); Dept. of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (B.M.E.); Dept. of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (W.P.M.);H. Lee Moffitt Cancer Center, Tampa, Florida (S.S.); F. Hoffman-La Roche, Ltd., Basel, Switzerland (L.E.A.); Exelixis, South San Francisco, California (D.T.A., G.M.S., C.H.); Dept. of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (A.L., P.L.N., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193027PMC
January 2017

Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.

J Magn Reson Imaging 2016 11 12;44(5):1229-1237. Epub 2016 Mar 12.

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.25227DOI Listing
November 2016

Biomarkers in NOA-04: another piece to the puzzle.

Neuro Oncol 2016 11;18(11):1467-1469

Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York (A.B.L.); Neuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (T.F.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063524PMC
November 2016

An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.

Cancer Cell 2016 Nov 13;30(5):683-693. Epub 2016 Oct 13.

Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093, USA; Department of Pathology, UCSD School of Medicine, La Jolla, CA 92093, USA; Moores Cancer Center, UCSD School of Medicine, La Jolla, CA 92093, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479636PMC
November 2016

Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T.

NMR Biomed 2016 11 15;29(11):1563-1576. Epub 2016 Sep 15.

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/nbm.3611
Publisher Site
http://dx.doi.org/10.1002/nbm.3611DOI Listing
November 2016

Large-scale assessment of the gliomasphere model system.

Neuro Oncol 2016 10 25;18(10):1367-78. Epub 2016 Apr 25.

Department of Biological Chemistry, University of California, Los Angeles, California (D.R.L.); Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience & Human Behavior, University of California, Los Angeles, California (T.J.C., M.Y.S.S., J.M., F.G., M.C.G., G.C., H.I.K.); Department of Pharmacology, University of California, Los Angeles, California (J.S.); Department of Pathology, University of California, Los Angeles, California (W.H.Y.); Department of Neurology, University of California, Los Angeles, California (T.F.C., A.L., G.C.); Department of Neurosurgery, University of California, Los Angeles, California (L.M.L.); Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, California (H.I.K.); The Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California (W.H.Y., T.F.C., L.M.L., A.L., H.I.K.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035518PMC
October 2016

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping.

Neuroimage Clin 2015 23;9:617-24. Epub 2015 Oct 23.

UCLA Neuro-Oncology Program, University of California, Los Angeles, 710 Westwood Plaza, Reed Building 1-230, Los Angeles, CA 90095, USA; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (CVIB), David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA 90024, USA; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA 90024, USA; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA 90024, USA; Department of Biomedical Physics, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA 90024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2015.10.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644251PMC
September 2016

PD-1 blockade enhances the vaccination-induced immune response in glioma.

JCI Insight 2016 Jul;1(10)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Brain Research Institute, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center (JCCC), David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.87059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951098PMC
July 2016

Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.

PLoS One 2015 27;10(10):e0141334. Epub 2015 Oct 27.

Department of Surgery/Surgical-Oncology, University of California Los Angeles, Los Angeles, California, United States of America; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141334PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624638PMC
June 2016

Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma.

Cancer 2016 06 21;122(11):1718-27. Epub 2016 Mar 21.

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29957DOI Listing
June 2016

Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma.

CNS Oncol 2015 22;4(4):247-56. Epub 2015 Jun 22.

Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, 924 Westwood Boulevard, Suite 615, Los Angeles, CA 90024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cns.15.16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538925PMC
April 2016

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Neuro Oncol 2016 Apr 8;18(4):557-64. Epub 2015 Oct 8.

University of California at San Francisco, San Francisco, California (N.B., A.P., J.P., A.M.M, M.P.); Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah (H.C.); The University of Texas MD Anderson Cancer Center, Houston, Texas (J.F.D.G.); Department of Neurology, Memorial Sloan Kettering Cancer Hospital, New York, New York (A.M.O.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (L.N., P.Y.W., S.H., K.L.L.); UCLA Medical Center, Los Angeles, California (T.F.C.); Plexxikon Inc., Berkeley, California (A.M., B.L.W., K.B.N., H.H.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (K.L.L.); Department of Pathology, Memorial Sloan Kettering Cancer Hospital, New York, New York (J.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799682PMC
April 2016

Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma.

Curr Neurol Neurosci Rep 2016 Feb;16(2):17

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave., Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11910-015-0613-6DOI Listing
February 2016

The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.

Neuro Oncol 2015 Dec 24;17(12):1589-98. Epub 2015 Apr 24.

Cure Brain Cancer Neuro-oncology Laboratory, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia (R.W.R., W.H., K.L.M.); Department of Medicine (Oncology), Stanford Cancer Institute, Stanford University, Stanford, California (F.W., M.P.H.); School of Public Health, Harbin Medical University, Harbin, People's Republic of China (F.W.); Department of Neurology, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California (H.N.N., T.F.C., A.L.); School of Medicine and Pharmacology, University of Western Australia, Perth, Australia (A.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633927PMC
December 2015

pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.

Neuro Oncol 2015 Nov 24;17(11):1514-24. Epub 2015 Jun 24.

Department of Radiological Sciences (R.J.H., W.B.P., B.M.E.), Department of Biomedical Physics (R.J.H., B.M.E.), Department of Neurology (T.F.C., A.L., P.L.N.), Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (L.M.L., R.M.P., J.P.A.); Department of Biomedical Sciences and Imaging, Cedars-Sinai Medical Center, Los Angeles, California (D.L.); Department of Bioengineering (D.L., B.M.E.), Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648305PMC
November 2015

Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI.

Clin Cancer Res 2015 Oct 21;21(19):4373-83. Epub 2015 Apr 21.

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, California. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California. Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2862DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592379PMC
October 2015

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.

Mol Cell 2015 Oct 8;60(2):307-18. Epub 2015 Oct 8.

Ludwig Institute for Cancer Research, La Jolla, CA 92093, USA; Department of Pathology, UCSD School of Medicine, La Jolla, CA 92093, USA; Moores Cancer Center, UCSD School of Medicine, La Jolla, CA 92093, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2015.09.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609298PMC
October 2015

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.

Neuro Oncol 2015 Sep 26;17(9):1275-83. Epub 2015 May 26.

Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA (P.Y.W.); Memorial Sloan Kettering Cancer Center, New York, New York, USA (A.O.); Cleveland Clinic, Cleveland, Ohio, USA (M.S.A.); University of Alabama, Birmingham, Alabama, USA (H.M.F.-S.); University of Rochester Medical Center, Rochester, New York, USA (N.M.); Sanofi, Cambridge, Massachusetts, USA (J.J.L); Exelixis Inc., South San Francisco, California, USA (A.D.L.); Quintiles, Durham, North Carolina, USA (J.T.); Sanofi, Bridgewater, New Jersey, USA (J.J.); Sanofi, Vitry-sur-Seine, France (C.E.); University of California-Los Angeles, Los Angeles, California, USA (T.F.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588757PMC
September 2015

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.

Cell Metab 2015 Sep 16;22(3):508-15. Epub 2015 Jul 16.

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2015.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663076PMC
September 2015

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Neuro Oncol 2015 Sep 5;17(9):1188-98. Epub 2015 Aug 5.

UCLA Neuro-Oncology Program and UCLA Brain Tumor Imaging Laboratory (BTIL), David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California (B.M.E., T.F.C.); Department of Radiological Sciences, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California (B.M.E., W.B.P.); Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany (M.B.); Department of Diagnostic Imaging, Warrne Alpert Medical School, Brown University, Providence, Rhode Island (J.B.); Department of Neuroradiology, Duke University School of Medicine, Durham, North Carolina (D.B.); Department of Radiology, Mayo Clinic, Rochester, Minnesota (B.J.E.); Department of Radiology, Erasmus MC University, Rotterdam, Netherlands (M.S.); Department of Radiology and Biomedical Imaging, University of California - San Francisco, San Francisco, California (S.J.N., S.C.); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts (E.G.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (B.A., P.Y.W.); Medical and Scientific Affairs, ICON Medical Imaging, Warrington, Pennsylvania (G.G., D.Y.); Department of Neurooncology, National Center of Tumor Disease, University Clinic Heidelberg, Heidelberg, Germany (W.W.); Department of Neurological Surgery, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio (M.V.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.); Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota (E.G.); Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (J.K.-C.); Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland (L.S., P.J.); Department of Radiation Oncology, University of Toronto and Princess Margaret

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588759PMC
September 2015

Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.

Tomography 2015 Sep;1(1):37-43

Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA; Dept. of Biomedical Physics, David Geffen School of Medicine at UCLA; Dept. of Bioengineering, Henry Samueli School of Engineering and Applied Science at UCLA; UCLA Neuro-Oncology Program; Dept. of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18383/j.tom.2015.00115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4698970PMC
September 2015

Toward precision medicine in glioblastoma: the promise and the challenges.

Neuro Oncol 2015 Aug 1;17(8):1051-63. Epub 2015 May 1.

University of California San Francisco, San Francisco, California (M.D.P, J.J.P., A.M.M., S.M.C.); Translational Genomics Research Institute, Phoenix, Arizona (S.A.B., N.L.T., W.D.T., J.A.K., M.E.B., D.W.C., J.D.C., J.M.T.); Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (K.L.L., P.Y.W.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); Memorial Sloan-Kettering Cancer Center, New York, New York (I.K.M.); The University of Texas M.D. Anderson Cancer Center, Houston, Texas (J.F.d.G.); University of Utah Huntsman Cancer Institute, Salt Lake City, Utah (H.C.); University of California Los Angeles, Los Angeles, California (T.F.C.); Iowa Spine and Brain Institute, Waterloo, Iowa (T.C.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nov031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490873PMC
August 2015

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.

Proc Natl Acad Sci U S A 2015 Jul 13;112(30):9406-11. Epub 2015 Jul 13.

Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093; Moores Cancer Center, University of California San Diego, La Jolla, CA 92093; Department of Pathology, University of California San Diego, La Jolla, CA 92093

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1511759112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522814PMC
July 2015

Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas.

Mol Imaging Biol 2015 Jun;17(3):434-42

Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-014-0807-3DOI Listing
June 2015

Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth.

Oncol Rep 2015 Jun 27;33(6):2883-8. Epub 2015 Apr 27.

Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2015.3926DOI Listing
June 2015

MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab.

J Neurooncol 2015 May 15;122(3):497-505. Epub 2015 Mar 15.

UCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-015-1755-8DOI Listing
May 2015

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.

Nat Rev Cancer 2015 May 9;15(5):302-10. Epub 2015 Apr 9.

Ludwig Institute for Cancer Research and the Department of Pathology, University of California San Diego, La Jolla, California 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3918DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875778PMC
May 2015

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Neuro Oncol 2015 Feb 26;17(2):180-8. Epub 2014 Aug 26.

Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (B.M.A., L.T., K.L.L., P.Y.W.); Mayo Clinic, Rochester, Minnesota (E.G., K.V.B., B.P.O., J.N.S.); The University of Texas M.D. Anderson Cancer Center, Houston, Texas (W.K.A.Y., J.F.D., D.A.B.); St. Jude Children's Research Hospital, Memphis, Tennessee (J.M.B.); University of California, Los Angeles, California (T.F.C.); Memorial Sloan-Kettering Cancer Center, New York, New York (J.T.H., I.K.M.); National Cancer Institute, Bethesda, Maryland (B.M., A.T.-A.); Princess Margaret Cancer Centre, Toronto, Ontario, Canada (W.M.); Henry Ford Hospital, Detroit, Michigan (T.M.); University of California, San Diego, La Jolla, California (P.S.M.); University of California, San Francisco, California (M.D.P.); Johns Hopkins University, Baltimore, Maryland (X.Y.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288520PMC
February 2015

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Neuro Oncol 2014 Nov 4;16(11):1541-6. Epub 2014 Jul 4.

Departments of Neurology (A.B.L., F.M.I., L.E.A., L.M.D.), Pathology (S.C.J., M.K.R.), Epidemiology & Biostatistics (A.S.R., K.S.P.), and the Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York; University of California, Los Angeles, Los Angeles, California (T.F.C.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (K.D.A., A.L.R.); Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (A.F.E., D.N.L.); NorthShore University Health System, Evanston Hospital Kellogg Cancer Center, University of Chicago, Pritzker School of Medicine, Evanston, Illinois (N.A.P.); London Regional Cancer Program, London, Ontario, Canada (B.J.F.); Barrow Neurological Institute, Phoenix, Arizona (L.S.A.); University of Calgary, Calgary, Alberta, Canada (J.G.C., G.B.R.U.); Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts (P.Y.W.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Children's Hospital Boston, Brigham and Women's Hospital, Boston, Massachusetts (K.L.L.); University of Virginia Health System, Charlottesville, Virginia (D.S.); University of Wisconsin, Madison, Wisconsin (H.I.R., B.G.R.); University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, Seattle, Washington (M.C.C.); Princess Margaret Hospital, Toronto, Ontario, Canada (W.P.M.); Albany Medical Center, Albany, New York (S.A.W.); Kaiser Permanente-Los Angeles Medical Center, Los Angeles, California (R.M.G.); Clemenceau Medical Center, Beirut, Lebanon and Université Saint-Esprit de Kaslik, Byblos, Lebanon (F.G.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201067PMC
November 2014

Pros and cons of current brain tumor imaging.

Neuro Oncol 2014 Oct;16 Suppl 7:vii2-11

Department of Radiological Sciences (B.M.E.), Department of Biomedical Physics, David Geffen School of Medicine at UCLA (B.M.E.); Department of Bioengineering, Henry Samueli School of Engineering and Applied Science at UCLA (B.M.E.); Brain Research Institute, David Geffen School of Medicine at UCLA (B.M.E., T.F.C.); UCLA Neuro-Oncology Program, David Geffen School of Medicine at UCLA, Los Angeles, California (B.M.E., T.F.C.); Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts (P.Y.W.); Department of Neuro-Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands (M.J.v.d.B.); Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California (T.F.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195528PMC
October 2014

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Neuro Oncol 2014 Oct;16 Suppl 7:vii36-47

Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (P.Y.W., D.A.R.); University of California, Los Angeles School of Medicine, Los Angeles, California (T.F.C., B.M.E., W.B.P.); New York University Langone Medical Center, New York, New York (H.A.F.); Hoffmann-La Roche, Basel, Switzerland (L.A.); Department of Biostatistics, Mayo Clinic Rochester, Rochester, Minnesota (K.B.); Department of Neuro-radiology, University of Heidelberg, Heidelberg, Germany (M.B.); Department of Medical Oncology, Mayo Clinic Rochester, Rochester, Minnesota (J.B.); Brain Tumor Center, University of California, San Francisco, California (S.M.C., M.D.P.); Siemens Healthcare North America, Malvern, Pennsylvania (A.G.S.); Department of Neuro-Oncology, Erasmus M.C.-Daniel den Hoed Cancer Center, Rotterdam, Netherlands (M.v.d.B.); Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, Texas (W-K.A.Y.).

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/neuonc/nou226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195530PMC
October 2014

¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.

Eur J Nucl Med Mol Imaging 2014 Jun 7;41(6):1199-209. Epub 2014 Mar 7.

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-6948, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-013-2678-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008691PMC
June 2014

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.

Neuro Oncol 2014 Jun 13;16(6):815-22. Epub 2014 Mar 13.

Department of Neurosciences, University of California San Diego, San Diego, California (D.E.P.); Department of Neurology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California (J.S., R.R.M., R.C., S.L., S.L., M.Z., P.L.N., T.F.C., A.L.); Department of Neurosurgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California (A.P.C., L.M.L.); Department of Pathology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California (D.E.S., W.H.Y.); Peterhouse, University of Cambridge, Cambridge, UK (J.W.); Department of Radiological Sciences, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California (B.M.E., W.B.P.); Kaiser Permanente Southern California, Los Angeles, California (J.Q., R.M.G.); Department of Biomathematics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California (H.W., R.E.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022228PMC
June 2014

Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.

Mol Cancer Res 2014 May 6;12(5):694-702. Epub 2014 Feb 6.

Authors' Affiliations: Department of Pediatrics, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance; Departments of 2Psychiatry and Molecular and Medical Pharmacology and 3Pediatrics; and 4The Jonsson Comprehensive Cancer Center, University of California Los Angeles (UCLA), Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-13-0576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020976PMC
May 2014

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Neuro Oncol 2014 Apr 26;16(4):567-78. Epub 2014 Jan 26.

Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (P.Y.W., A.D.N., J.D.); Department of Neurosurgery, University of California, San Francisco, San Francisco, California (S.M.C., K.R.L., M.D.P.); University of Texas Health Science Center, San Antonio, Texas (J.G.K.); Division of Neuro-Oncology, Department of Neurology, University of California, Los Angeles, Los Angeles, California (T.F.C.); University of Wisconsin, Madison Wisconsin (H.I.R., M.P.M.); Neurooncology Program, Division of Hematology/Oncology, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, Pennsylvania (F.S.L.); Division of Neuro-Oncology, MD Anderson Cancer Center, Houston, Texas (M.R.G., M.D.G., W.K.A.Y., K.D.A.); Center for Molecular Oncologic Pathology, Dana Farber/Brigham and Women's Cancer Center, Boston, Massachusetts (S.S., A.H.L.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.S., A.H.L., K.L.L.); Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland (J.D.*, J.J.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/not247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956354PMC
April 2014

Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Radiology 2014 Apr 27;271(1):200-10. Epub 2013 Nov 27.

From the Departments of Radiological Sciences (B.M.E., H.J.K., D.C.W., W.B.P., J.N.C., R.J.H.), Biomedical Physics (B.M.E., D.C.W., R.J.H.), and Neurology (A.L., P.L.N., T.F.C.), David Geffen School of Medicine, University of California-Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA 90024; and Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California-Los Angeles, Los Angeles, Calif (B.M.E.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.13131305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263651PMC
April 2014

The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings.

Clin Biochem 2014 Mar 12;47(4-5):258-66. Epub 2014 Jan 12.

Department of Pathology and Laboratory Medicine (Neuropathology), David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Brain Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2014.01.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982909PMC
March 2014

C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.

J Neurooncol 2014 Mar 29;117(1):53-65. Epub 2014 Jan 29.

Department of Biological Chemistry, David Geffen School of Medicine at UCLA, 615 Charles E. Young Dr. South, Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11060-014-1371-z
Publisher Site
http://dx.doi.org/10.1007/s11060-014-1371-zDOI Listing
March 2014